Trimethoprim-Sulfamethoxazole & Infant Birth Weight: HIV Study
Trimethoprim-Sulfamethoxazole in Pregnancy: A Zimbabwe Study Finds No Significant Impact on Birth Weight
Table of Contents
Antenatal care is a cornerstone of maternal and infant health, especially in regions with high rates of infectious disease.A recent clinical trial conducted in Zimbabwe investigated whether routine governance of trimethoprim-sulfamethoxazole (TMP-SMX) during pregnancy could improve birth outcomes. The study, published in the New England Journal of Medicine, offers valuable insights into a pragmatic approach to improving birth weight in a setting with a high HIV prevalence.
Study Design and Methods
The randomized, placebo-controlled trial enrolled 993 pregnant women in Zimbabwe. Participants were assigned to recieve either TMP-SMX or a placebo,beginning at a median gestational age of 21.7 weeks. The study aimed to evaluate the impact of worldwide TMP-SMX prophylaxis on birth weight and other key maternal and neonatal outcomes.
Researchers collected extensive data throughout the study period. This included detailed obstetrical histories, facts regarding HIV status, and regular blood pressure measurements. Fetal growth was monitored using ultrasonography at 26 and 34 weeks’ gestation. To ensure participant safety, liver function, kidney function, and complete blood counts were routinely assessed. Weekly telephone calls, starting at 36 weeks’ gestation, were used to track deliveries and gather information on maternal and neonatal well-being.
The primary outcome measure was birth weight. Secondary outcomes included rates of low birth weight, gestational duration, preterm birth, small for gestational age (SGA), fetal loss (miscarriage and stillbirth), maternal hospitalization or death, and neonatal hospitalization or death. Investigators also calculated z-scores for weight-for-age, length-for-age, and head circumference to provide a standardized assessment of fetal growth.
Key Findings: Birth Outcomes
The study population had a median age of 24.5 years and a median gestational age of 20.4 weeks at enrollment. Notably, 13.2% of participants were living with HIV.
Over the course of the study, there were 17 miscarriages, 19 stillbirths, and 928 live births, including 14 sets of twins. The analysis revealed no statistically significant difference in mean birth weight between the TMP-SMX group (3040 ± 460 g) and the placebo group (3019 ± 526 g). The mean difference of 20 g was not statistically significant.Similarly, rates of secondary outcomes were comparable between the two groups.The rate of low birth weight was 10% in the TMP-SMX group and 11.6% in the placebo group.
Secondary outcome Details
Further analysis of secondary outcomes showed similar trends. The rate of infants born small for gestational age was 20.3% in the TMP-SMX group and 17.3% in the placebo group. Fetal loss occurred in 4.2% of pregnancies in the TMP-SMX group and 3.3% in the placebo group. Mean gestational age at birth was 39.3 weeks in the TMP-SMX group and 38.9 weeks in the placebo group. Importantly, the incidence of adverse events was also similar between the two groups, suggesting the intervention was well-tolerated.
Implications for Maternal and Infant Health
The investigators concluded that a universal antenatal TMP-SMX strategy, implemented in a Zimbabwean district with a high HIV prevalence, did not considerably improve birth weight. This finding has important implications for public health strategies aimed at reducing adverse birth outcomes in resource-limited settings.
While TMP-SMX is known to be effective in preventing certain infections, this study suggests that its routine use as a broad prophylactic measure may not be the most effective approach to improving birth weight in this context. Further research is needed to identify targeted interventions that address the specific underlying causes of low birth weight and preterm birth in populations with high rates of HIV and other infectious diseases.
This research underscores the complexity of improving birth outcomes and highlights the need for nuanced,evidence-based strategies tailored to the specific needs of different populations. Future studies should explore choice or complementary interventions, such as improved nutrition, enhanced antenatal care, and targeted treatment of specific infections, to optimize maternal and infant health.References
- Chasekwa B, Munhanzi F, Madhuyu L, et al. A trial of trimethoprim-